Welcome to our dedicated page for Fennec Pharmaceuticals SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
An insider associated with FENC has filed a notice of intent to sell 10,349 common shares through Morgan Stanley Smith Barney LLC on or around 02/02/2026, with the shares to be sold on NASDAQ.
The shares were acquired the same day via a stock option exercise paid in cash. Over the prior three months, the same seller, Rostislav Raykov, sold additional blocks of common stock totaling 30,312 shares for gross proceeds of about $235,000. The issuer had 28,116,829 shares outstanding when this notice was prepared.
Fennec Pharmaceuticals director Rosty Raykov reported a routine equity change as 5,208 common shares were acquired on January 31, 2026 at a price of $0 per share. These shares were released from restrictions tied to awards originally granted on March 31, 2023 and May 16, 2024.
Following this release of previously awarded stock, Raykov directly beneficially owns 93,228 common shares of Fennec Pharmaceuticals. The filing reflects a non-cash change in ownership from restricted to freely releasable shares rather than an open-market purchase or sale.
Fennec Pharmaceuticals chief financial officer Robert Andrade reported an equity change in the company’s common shares. On January 31, 2026, he acquired 1,558 common shares at a price of $0 per share through the release of restrictions on previously awarded shares.
These shares were released from restriction from awards originally granted on March 31, 2023 and May 16, 2024. Following this vesting event, Andrade directly holds a total of 212,658 common shares of Fennec Pharmaceuticals.
Fennec Pharmaceuticals Inc. chief financial officer exercises stock options for 10,000 shares. On January 23, 2026, CFO Robert Andrade exercised stock options with a strike price of $2.45 per share, acquiring 10,000 common shares of Fennec Pharmaceuticals Inc. following an option contract that was scheduled to expire on July 5, 2026.
After this transaction, Andrade directly held 211,100 common shares of Fennec and still held 816,567 stock options with an exercise price of $2.45, according to the filing.
Fennec Pharmaceuticals Inc. reported an insider transaction by its Chief Financial Officer, Robert Andrade. On 01/15/2026, he exercised 10,000 stock options with an exercise price of $2.45 per share, acquiring 10,000 common shares.
Following the transaction, Andrade directly beneficially owned 201,100 common shares and held 826,567 stock options that remained outstanding. The shares were acquired through the exercise of an option contract with a strike price of $2.45 and an expiration date of July 5, 2026.
Fennec Pharmaceuticals Inc. received an updated ownership filing showing that investment entities affiliated with Southpoint report beneficial ownership of 2,744,741 Common Shares, representing 8.0% of the company. These shares are held by Southpoint Master Fund, LP, with related management and general partner entities, and by John S. Clark II in his capacities with those entities.
The reported ownership percentage is based on 34,153,496 outstanding Common Shares, as disclosed in a Prospectus Supplement filed on November 18, 2025. The reporting parties state that each of them disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest.
Fennec Pharmaceuticals chief financial officer Robert Andrade reported exercising stock options and acquiring common shares of the company. On January 7, 2026, he exercised 14,184 stock options at an exercise price of $2.45 per share, which resulted in acquiring 14,184 common shares. After this transaction, he beneficially owned 191,100 common shares directly and held 836,567 stock options directly.
Fennec Pharmaceuticals director reports vested share award
A director of Fennec Pharmaceuticals Inc. reported the acquisition of 5,208 common shares of the company on 12/01/2025. The filing shows these shares were released from restrictions tied to awards originally granted on 3/31/2023 and 5/16/2024, so no purchase price was paid and the transaction is recorded at $0 per share.
Following this vesting event, the director now beneficially owns 87,526 common shares, held directly. The transaction was reported on a Form 4 filed for a single reporting person in the capacity of director of Fennec Pharmaceuticals Inc. (FENC).
Fennec Pharmaceuticals (FENC) reported an insider share sale by a major holder. On 11/18/2025, an affiliated fund of Southpoint, for which John S. Clark II and related Southpoint entities serve as general partners and managers, sold 19,341 shares of Fennec common stock in open-market transactions. The weighted average sale price was $8.7921 per share across trades executed between $8.75 and $8.845 per share. After this sale, the reporting persons collectively report 3,744,741 shares of Fennec common stock beneficially owned indirectly, while each disclaims beneficial ownership beyond their pecuniary interest.
Fennec Pharmaceuticals Inc. (FENC) has fully repurchased and redeemed its remaining senior secured floating rate convertible notes held by Petrichor. On November 17, 2025, the company paid a total redemption price of $21,729,455.30, consisting of $19,476,655.48 in outstanding principal (including accrued PIK interest), $305,134.27 in accrued interest, and a $1,947,665.55 redemption fee. This follows an earlier repurchase and redemption of notes with an aggregate principal amount of $13,000,000. After this transaction, all payment obligations under the notes have been satisfied in full.